Abstract: A non-radioisotopic method of detecting thyroid analytes comprising detecting T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in a sample of a non-human species. Each one of these analytes in an assay profile includes non-radio isotopic measurement of T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in the sample from the non-human species. A non-radioisotopic method detects T3AA and T4AA thyroid autoantibodies in a sample from a non-human species such as the canine species. Antibodies and autoantibodies are bound, and a precipitated or bound antigen-antigen or antibody-autoantibody complex is formed. The supernatant or surrounding fluid of the bound or precipitated antigen-antigen or antibody-autoantibody complex is then removed. The thyroid activity of the bound complex, precipitate, supernatant or surrounding fluid is measured. The thyroid analyte is at least one of T3, Free T3, T4 or Free T4.

Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.

Abstract: The invention provides methods and devices for detecting the presence of one or more target analytes in a sample employing a channel having affixed therein one or more binding partners for each target analyte. Assays are carried out by transporting the sample through the channel to each successive binding partner so that target analyte present in said sample binds to the corresponding binding partner. The sample is then transported beyond the binding partner(s), followed by detection of any target analyte bound to each binding partner. In one embodiment, binding efficiency is increased by the use of segmented transport, wherein a first bolus or bubble of a fluid that is immiscible with the sample precedes the sample during transport and a second bolus or bubble of a fluid that is immiscible with the sample follows the sample. Many configurations are possible for the device of the invention.

Abstract: A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody.

Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.

Abstract: An implantable medical device is provided for use with an external detector to detect an analyte in vivo. In one embodiment, the device consisting essentially of a substrate; a plurality of discrete reservoirs located in the substrate, each reservoir having at least one opening; a reacting component contained in each reservoir; and at least one non-degradable barrier layer covering each reservoir opening, the barrier layer being permeable to an analyte to be detected, wherein the reacting component remains inside the reservoirs and can react with the analyte to be detected, and wherein the device is adapted for implantation into the body of a patient.

Abstract: The present invention is directed to a method identifying a risk for a thrombogenic disorder, to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.

Abstract: There is provided a simple, inexpensive reaction analysis kit and system capable of performing highly sensitive, quantitative measurement. A chemical luminescence reaction is employed and a sensor element is used to detect the reaction in a highly sensitive manner. That is, a reaction detection plate is used to transmit a signal detected in the sensor element via a reader coil and a reader and then analyze the reaction. The reaction detection plate has a) a membrane, b) a first antibody impregnated section that is disposed such that it faces the membrane and holds a first labeled antibody that specifically binds to a substance to be analyzed, c) a second antibody immobilized section that is provided in part of the membrane and has an immobilized second antibody, the second antibody specifically binding to the substance to be analyzed, and d) a sensor element that is disposed such that it faces the second antibody immobilized section and includes a light detector and a signal transceiver.

Abstract: A particle analyzer in which tagged particles to be analyzed are drawn through a suspended capillary tube where a predetermined volume in the capillary tube is illuminated. The illumination scattered by said particles is detected by a detector to count all particles. The fluorescent illumination emitted by tagged particles is detected and the output signals from the fluorescent detectors and scatter detector are processed to provide an analysis of the particles.

Abstract: The present invention provides a protein-immobilized carrier which can realize highly efficient use of an immobilized antibody and prevent non-specific binding. A protein-immobilized carrier including a porous body having mesopores characterized in that the carrier has mesopores having an organic substance adsorbed therein other than an antibody, an antigen or a fragment thereof having a particle size smaller than the pore size of the mesopores and having an antibody, an antigen or a fragment thereof physically adsorbed and immobilized from the pore entrance to a depth of not more than the pore size in the depth direction of the mesopores.

Abstract: The present invention relates to a process for detecting one or more analytes in one or more samples of biological origin having complex composition. The present invention also relates to a microarray for quantitative determination of one or more analytes in samples of biological origin having complex composition which are immobilized in measurement ranges of microarray, and also to a quantitative detection method based thereon.

Abstract: A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody.

Abstract: A device and method is disclosed for improving the detection of a ligand by a receptor by concentrating microbes by removing particulates from fluid-borne samples and/or causing selective aggregation of concentrated microbes. The device may be configured as a multipath valve capable purifying/concentrating a sample in one orientation and delivering the concentrated sample in another orientation. In one embodiment, the device includes a body that defines a plurality of chambers and pathways and supports a pathogen capture unit that houses a receptor that exhibits specificity for a ligand. In another embodiment, the capture unit houses a plurality of antibody coated generally spherical particles capable of binding to a ligand.

Abstract: An electrochemical-based assay device capable of detecting the presence or quantity of an analyte of interest that is provided. The device contains two or more substrates, one containing a detection working electrode and another containing an auxiliary electrode, such as a counter/reference electrode(s). The substrates are positioned in a face-to-face relationship so that the electrodes are adjacent to each other during performance of the assay. Besides the electrodes, any of a variety of other components may also be employed in the assay device.

Abstract: The present invention provides a method for detecting a target substance by detecting the presence or concentration of a target substance in a sample solution by bringing the sample solution into contact with a detecting element including a detecting part and a non-detecting part and detecting the presence or number of a magnetic label (magnetic marker) present in the vicinity of the surface of the detecting part and provides a target-substance detection kit.

Abstract: The present invention proves instruments and methods for detecting and/or quantitating an analyte in a fluid sample. The fluid sample is placed in a sample chamber having a small, shallow detection region. The analyte is magnetically labeled using magnetic particles coated with a binding reagent, and is detectably labeled using a fluorescent dye or other detection reagent. The magnetically labeled analyte is concentrated into the detection region using a focusing magnet positioned underneath the sample chamber detection region. Concentrated analyte is measured using excitation optics positioned on top of the sample chamber detection region, adapted to illuminate only the detection region, and detection optics positioned on top of the detection region, adapted to detect only light emitted from the detection region. In a preferred embodiment, the invention provides a simple, rapid assay for measuring the concentration of CD4+T cells in a whole blood sample.

Abstract: A device includes a planar optical waveguide, as part of a sensor platform, and, connected to the platform directly or by means of a sealing medium, a sealing layer. The sealing layer forms either directly or by means of a sealing medium a tightly sealing layer. The sealing layer includes a multitude of recesses at least open towards the sensor platform, which form a corresponding multitude of sample compartments in a 2-dimensional arrangement.

Abstract: A biological molecule-immobilized chip is produced by: allowing a biological molecule having a portion capable of forming coordination bond to a metal ion to form a coordination bond to a metal ion, bringing the resultant complex adjacent to an electrically conductive support, and applying reduction potential to the electrically conductive support.

Abstract: An electrochemical immunosensor system with reduced interference, comprising: a first immunosensor that generates an electrochemical signal based on the formation of a sandwich between an immobilized antibody, a target analyte and a labeled antibody, wherein a portion of the signal arises from non-specific binding of the labeled antibody in the region of the first immunosensor, and a second immunosensor that acts as an immuno-reference sensor and generates a signal that is the same as or predictably related to the degree of non-specific binding which occurs in the region of the first immunosensor, and has an immunocomplex between an immobilized antibody and an endogenous or exogenous protein that is in the sample and that is not the target analyte.

Abstract: A lanthanide chelate is linked to a noble metal substrate at a proximity wherein the substrate enhances a fluorescent emission of the lanthanide by at least 20-fold when the chelate is illuminated at an excitation wavelength that induces a transition in the lanthanide that results in the fluorescent emission.